Biogen Inc 0R1B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 0R1B is a good fit for your portfolio.
News
-
Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves
-
'Patients got better faster': Music therapy provides new hope after strokes.
-
Biogen's stock slides as quarterly results miss expectations amid slow launch of Alzheimer's treatment
-
Biogen's Skyclarys Treatment for Friedreich's Ataxia Authorized by European Commission
-
Biogen drops controversial Alzheimer's drug
-
Biogen 'welcomes' EC decision to revoke CMAs for generic versions of Tecfidera
-
Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatment
-
Biogen and Eisai release new Alzheimer's drug data that may support wider uptake
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 20.57
- Price/Sales
- 4.10
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 6.38%
Company Profile
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Value
- Total Number of Employees
- 7,570
- Website
- https://www.biogen.com
Competitors
Valuation
|
Metric
|
0R1B
|
NVS
|
SNY
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.57 | 14.12 | 10.78 |
Price/Book Value | 4.24 | 5.01 | 1.61 |
Price/Sales | 4.10 | 4.05 | 2.44 |
Price/Cash Flow | 16.32 | 13.44 | 12.02 |
Price/Earnings
0R1B
NVS
SNY
Financial Strength
|
Metric
|
0R1B
|
NVS
|
SNY
|
|---|---|---|---|
Quick Ratio | 0.95 | 0.61 | 0.83 |
Current Ratio | 2.10 | 0.90 | 1.27 |
Interest Coverage | 5.38 | 11.32 | 8.40 |
Quick Ratio
0R1B
NVS
SNY
Profitability
|
Metric
|
0R1B
|
NVS
|
SNY
|
|---|---|---|---|
Return on Assets (Normalized) | 8.32% | 13.39% | — |
Return on Equity (Normalized) | 15.02% | 31.09% | — |
Return on Invested Capital (Normalized) | 10.29% | 19.67% | — |
Return on Assets
0R1B
NVS
SNY
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Vjpsgflfsv | Wgq | $697.4 Bil | |
JNJ
| Johnson & Johnson | Lwpjhbl | Rwq | $353.8 Bil | |
MRK
| Merck & Co Inc | Fnjjwnx | Skjf | $332.3 Bil | |
ABBV
| AbbVie Inc | Zvyqbnmpq | Mlk | $282.6 Bil | |
AZN
| AstraZeneca PLC ADR | Bmplsynlfx | Zclb | $232.3 Bil | |
NVS
| Novartis AG ADR | Rvstdzlm | Hxgr | $200.1 Bil | |
RHHBY
| Roche Holding AG ADR | Gjffpfrht | Dwhv | $195.3 Bil | |
AMGN
| Amgen Inc | Klssyzdpl | Rln | $144.5 Bil | |
PFE
| Pfizer Inc | Sxshqkx | Qrl | $143.8 Bil | |
SNY
| Sanofi SA ADR | Pvwmqpt | Spxk | $122.2 Bil |